Does tocilizumab have a magical therapeutic effect on COVID-19 patients without obvious adverse reactions?
作者信息
Wang Yong, Mao Qing, Zhou Xiangdong
机构信息
Department of Rheumatology, Southwest Hospital, Army Medical University (the Third Military Medical University), Chongqing 400038, People's Republic of China.
Department of Infection, Taikang Tongji COVID-19 Hospital, Wuhan 430000, People's Republic of China.
出版信息
Proc Natl Acad Sci U S A. 2020 Dec 8;117(49):30896-30897. doi: 10.1073/pnas.2009961117. Epub 2020 Nov 17.
Abstract
摘要
相似文献
1
Does tocilizumab have a magical therapeutic effect on COVID-19 patients without obvious adverse reactions?
Proc Natl Acad Sci U S A. 2020 Dec 8;117(49):30896-30897. doi: 10.1073/pnas.2009961117. Epub 2020 Nov 17.
2
[COVID-19: Still a place for tocilizumab?].
Rev Med Interne. 2021 Feb;42(2):73-78. doi: 10.1016/j.revmed.2020.11.016. Epub 2020 Nov 27.
3
Tocilizumab for Covid-19 - The Ongoing Search for Effective Therapies.
N Engl J Med. 2020 Dec 10;383(24):2387-2388. doi: 10.1056/NEJMe2032071.
4
Reply to Yang et al.: Tocilizumab treatment in COVID-19 patients needs the assessment of the disease severity and timely intervention.
Proc Natl Acad Sci U S A. 2020 Dec 1;117(48):30027-30028. doi: 10.1073/pnas.2011616117. Epub 2020 Nov 12.
5
Vascular microthrombosis associated with increased interleukin-6. A severe acute respiratory distress syndrome in COVID-19 patients treated with tocilizumab.
Adv Respir Med. 2020;88(5):468-469. doi: 10.5603/ARM.a2020.0123.
6
The effect of tocilizumab on severe COVID-19 infection: Review of current evidence.
Tuberk Toraks. 2021 Mar;69(1):74-83. doi: 10.5578/tt.20219909.
7
Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment.
Mult Scler Relat Disord. 2020 Nov;46:102592. doi: 10.1016/j.msard.2020.102592. Epub 2020 Oct 21.
8
Impact of Timing of Tocilizumab Use in Hospitalized Patients With SARS-CoV-2 Infection.
Respir Care. 2022 May;67(5):629-630. doi: 10.4187/respcare.10067.
9
Tocilizumab prescribing criteria for COVID-19 patients.
Hum Vaccin Immunother. 2021 Apr 3;17(4):1128. doi: 10.1080/21645515.2020.1822137. Epub 2020 Oct 20.
10
Testing the efficacy of tocilizumab in patients with COVID-19 pneumonia.
J Comp Eff Res. 2021 Jun;10(8):625-627. doi: 10.2217/cer-2021-0050. Epub 2021 Apr 23.
引用本文的文献
1
Therapeutic Impact of Tocilizumab in the Setting of Severe COVID-19; an Updated and Comprehensive Review on Current Evidence.
Arch Acad Emerg Med. 2024 May 9;12(1):e47. doi: 10.22037/aaem.v12i1.2217. eCollection 2024.
2
Tocilizumab, an Exploratory Treatment for Severe COVID-19 Patients.
Can J Infect Dis Med Microbiol. 2022 Mar 15;2022:6375870. doi: 10.1155/2022/6375870. eCollection 2022.
3
Increased Circulating Cytokines Have a Role in COVID-19 Severity and Death With a More Pronounced Effect in Males: A Systematic Review and Meta-Analysis.
Front Pharmacol. 2022 Feb 14;13:802228. doi: 10.3389/fphar.2022.802228. eCollection 2022.
4
Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19).
Leukemia. 2021 Jun;35(6):1661-1670. doi: 10.1038/s41375-021-01264-8. Epub 2021 May 17.
5
Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment.
Front Immunol. 2021 Mar 4;12:598799. doi: 10.3389/fimmu.2021.598799. eCollection 2021.
6
Therapeutic efficacy, mechanical ventilation, length of hospital stay, and mortality rate in severe COVID-19 patients treated with tocilizumab.
Int J Clin Pract. 2021 Jun;75(6):e14079. doi: 10.1111/ijcp.14079. Epub 2021 Mar 17.
7
Reply to Wang et al.: Tocilizumab treatment should be used in a timely manner, at suitable dose, and in suitable patients.
Proc Natl Acad Sci U S A. 2020 Dec 8;117(49):30898-30899. doi: 10.1073/pnas.2017204117. Epub 2020 Nov 17.
本文引用的文献
1
Effective treatment of severe COVID-19 patients with tocilizumab.
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
2
Tocilizumab treatment in COVID-19: A single center experience.
J Med Virol. 2020 Jul;92(7):814-818. doi: 10.1002/jmv.25801. Epub 2020 Apr 15.
3
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.
Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24.
4
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
5
Patterns of tocilizumab use, effectiveness and safety in patients with rheumatoid arthritis: core data results from a set of multinational observational studies.
Clin Exp Rheumatol. 2017 Nov-Dec;35(6):899-906. Epub 2017 Apr 28.
6
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.
Lancet. 2016 Jun 25;387(10038):2630-2640. doi: 10.1016/S0140-6736(16)00232-4. Epub 2016 May 5.
7
Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.
Blood. 2008 Nov 15;112(10):3959-64. doi: 10.1182/blood-2008-05-155846. Epub 2008 Sep 10.
Zotero 插件